PL2922576T3 - Sposoby podawania i oceny leków wychwytujących azot do leczenia encefalopati wątrobowej - Google Patents
Sposoby podawania i oceny leków wychwytujących azot do leczenia encefalopati wątrobowejInfo
- Publication number
- PL2922576T3 PL2922576T3 PL13857455T PL13857455T PL2922576T3 PL 2922576 T3 PL2922576 T3 PL 2922576T3 PL 13857455 T PL13857455 T PL 13857455T PL 13857455 T PL13857455 T PL 13857455T PL 2922576 T3 PL2922576 T3 PL 2922576T3
- Authority
- PL
- Poland
- Prior art keywords
- encefalopati
- hepatic
- administration
- evaluation
- nitrogen
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Ecology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261728967P | 2012-11-21 | 2012-11-21 | |
| US201361759292P | 2013-01-31 | 2013-01-31 | |
| PCT/US2013/071333 WO2014081977A1 (en) | 2012-11-21 | 2013-11-21 | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
| EP13857455.3A EP2922576B1 (en) | 2012-11-21 | 2013-11-21 | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2922576T3 true PL2922576T3 (pl) | 2018-08-31 |
Family
ID=50728524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13857455T PL2922576T3 (pl) | 2012-11-21 | 2013-11-21 | Sposoby podawania i oceny leków wychwytujących azot do leczenia encefalopati wątrobowej |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9289406B2 (pl) |
| EP (2) | EP2922576B1 (pl) |
| JP (1) | JP2016506378A (pl) |
| KR (1) | KR20150086510A (pl) |
| CN (1) | CN104797272A (pl) |
| AU (1) | AU2013347905B2 (pl) |
| BR (1) | BR112015011778A2 (pl) |
| CA (1) | CA2891657A1 (pl) |
| CY (1) | CY1120163T1 (pl) |
| DK (1) | DK2922576T3 (pl) |
| ES (1) | ES2654774T3 (pl) |
| HK (1) | HK1210699A1 (pl) |
| HR (1) | HRP20180041T1 (pl) |
| HU (1) | HUE036133T2 (pl) |
| LT (1) | LT2922576T (pl) |
| PL (1) | PL2922576T3 (pl) |
| PT (1) | PT2922576T (pl) |
| RS (1) | RS56757B1 (pl) |
| SI (1) | SI2922576T1 (pl) |
| SM (1) | SMT201800022T1 (pl) |
| WO (1) | WO2014081977A1 (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG174982A1 (en) | 2009-04-03 | 2011-11-28 | Ocera Therapeutics Inc | L-ornithine phenyl acetate and methods of making thereof |
| JP5749255B2 (ja) | 2009-06-08 | 2015-07-15 | ユーシーエル ビジネス ピーエルシー | Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 |
| DK2760479T3 (en) | 2011-09-30 | 2017-07-17 | Horizon Therapeutics Llc | Nitrogen-removing drug for use in a method of treating a nitrogen retention disorder |
| CN104540507A (zh) | 2012-04-20 | 2015-04-22 | 海波龙治疗公司 | 苯乙酸前药的治疗性监测方法 |
| US9289406B2 (en) * | 2012-11-21 | 2016-03-22 | Horizon Therapeutics, Inc. | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
| IL281349B (en) | 2014-11-24 | 2022-09-01 | Ucl Business Ltd | Treatment of diseases related to hepatic stellate cell activity using ammonia-lowering treatments |
| US10835506B2 (en) | 2015-08-18 | 2020-11-17 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
| US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
| CA3063134A1 (en) | 2017-05-11 | 2018-11-15 | Ocera Therapeutics, Inc. | Processes of making l-ornithine phenylacetate |
| US10668040B2 (en) | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
| AU2021340882A1 (en) | 2020-09-14 | 2023-05-25 | Pharma Cinq, Llc | 2',3'-diacetyluridine substituted with acetoacetyl at the 5' position |
| CA3199559A1 (en) * | 2020-12-01 | 2022-06-09 | Rolando Alejandro GARCIA GARCIA | 5'-o-phenylacetyluridine and therapeutic use |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| US5635532A (en) | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
| US5879657A (en) | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
| DE69612755T2 (de) | 1995-02-07 | 2001-08-23 | Brusilow Enterprises, Llc | Triglyceride und ethylester von phenylalkansäuren und phenylalkensäuren zur behandlung verschiedener erkrankungen |
| US6219567B1 (en) | 1999-06-21 | 2001-04-17 | Cardiox Corporation | Monitoring of total ammoniacal concentration in blood |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| US20050273359A1 (en) | 2004-06-03 | 2005-12-08 | Young David E | System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure |
| CN1778963A (zh) * | 2004-11-23 | 2006-05-31 | 苏州艾杰生物科技有限公司 | 血氨含量测定方法及血氨诊断试剂盒 |
| PL1824563T3 (pl) | 2004-11-26 | 2010-07-30 | Ucl Business Plc | Kompozycje zawierające ornitynę i fenylooctan lub fenylomaślan do leczenia encefalopatii wątrobowej |
| US20060135612A1 (en) | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| US20070004805A1 (en) | 2005-07-01 | 2007-01-04 | Navinta Llc | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
| US20100016207A1 (en) | 2005-11-10 | 2010-01-21 | Wurtman Richard J | Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid |
| US8094521B2 (en) | 2007-02-28 | 2012-01-10 | Nightingale Products LLC | Caregiver personal alert device |
| EP2237684A2 (en) | 2008-01-08 | 2010-10-13 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
| GB2465250B (en) | 2008-08-29 | 2011-01-26 | Ucyclyd Pharma Inc | Dosing and monitoring patients on nitrogen-scavenging drugs |
| PL3133396T3 (pl) | 2008-04-29 | 2019-03-29 | Horizon Therapeutics, Llc | Sposób leczenia z zastosowaniem leków wychwytujących amoniak |
| PT3133396T (pt) * | 2008-08-29 | 2018-12-07 | Immedica Pharma Ab | Métodos de tratamento utilizando fármacos eliminadores de amoníaco |
| WO2011011781A1 (en) | 2009-07-24 | 2011-01-27 | Baylor College Of Medicine | Methods of modulation of branched chain acids and uses thereof |
| WO2012028620A1 (en) | 2010-08-31 | 2012-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation |
| DK2760479T3 (en) * | 2011-09-30 | 2017-07-17 | Horizon Therapeutics Llc | Nitrogen-removing drug for use in a method of treating a nitrogen retention disorder |
| CN104540507A (zh) * | 2012-04-20 | 2015-04-22 | 海波龙治疗公司 | 苯乙酸前药的治疗性监测方法 |
| US9289406B2 (en) * | 2012-11-21 | 2016-03-22 | Horizon Therapeutics, Inc. | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
| WO2015048818A1 (en) | 2013-09-30 | 2015-04-02 | Hyperion Therapeutics, Inc. | Diagnosing, grading, monitoring, and treating hepatic encephalopathy |
| ES2746999T3 (es) | 2013-10-14 | 2020-03-09 | Immedica Pharma Ab | Métodos de tratamiento de trastornos del ciclo de la urea |
-
2013
- 2013-11-21 US US14/086,870 patent/US9289406B2/en active Active
- 2013-11-21 WO PCT/US2013/071333 patent/WO2014081977A1/en not_active Ceased
- 2013-11-21 DK DK13857455.3T patent/DK2922576T3/en active
- 2013-11-21 PL PL13857455T patent/PL2922576T3/pl unknown
- 2013-11-21 SM SM20180022T patent/SMT201800022T1/it unknown
- 2013-11-21 RS RS20180035A patent/RS56757B1/sr unknown
- 2013-11-21 CN CN201380061003.XA patent/CN104797272A/zh active Pending
- 2013-11-21 HR HRP20180041TT patent/HRP20180041T1/hr unknown
- 2013-11-21 HU HUE13857455A patent/HUE036133T2/hu unknown
- 2013-11-21 LT LTEP13857455.3T patent/LT2922576T/lt unknown
- 2013-11-21 SI SI201330898T patent/SI2922576T1/en unknown
- 2013-11-21 EP EP13857455.3A patent/EP2922576B1/en active Active
- 2013-11-21 KR KR1020157016078A patent/KR20150086510A/ko not_active Withdrawn
- 2013-11-21 JP JP2015544137A patent/JP2016506378A/ja active Pending
- 2013-11-21 BR BR112015011778A patent/BR112015011778A2/pt not_active IP Right Cessation
- 2013-11-21 CA CA2891657A patent/CA2891657A1/en not_active Withdrawn
- 2013-11-21 EP EP17200153.9A patent/EP3335735A1/en not_active Withdrawn
- 2013-11-21 ES ES13857455.3T patent/ES2654774T3/es active Active
- 2013-11-21 AU AU2013347905A patent/AU2013347905B2/en not_active Ceased
- 2013-11-21 HK HK15111438.0A patent/HK1210699A1/xx unknown
- 2013-11-21 PT PT138574553T patent/PT2922576T/pt unknown
-
2016
- 2016-02-15 US US15/043,859 patent/US20160223520A1/en not_active Abandoned
-
2017
- 2017-08-08 US US15/672,196 patent/US20180017546A1/en not_active Abandoned
-
2018
- 2018-01-25 CY CY20181100103T patent/CY1120163T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013347905A1 (en) | 2015-04-30 |
| HRP20180041T1 (hr) | 2018-06-01 |
| RS56757B1 (sr) | 2018-04-30 |
| ES2654774T3 (es) | 2018-02-15 |
| HUE036133T2 (hu) | 2018-06-28 |
| EP2922576B1 (en) | 2017-11-08 |
| US20180017546A1 (en) | 2018-01-18 |
| US20160223520A1 (en) | 2016-08-04 |
| DK2922576T3 (en) | 2018-01-15 |
| PT2922576T (pt) | 2018-01-24 |
| WO2014081977A1 (en) | 2014-05-30 |
| AU2013347905B2 (en) | 2018-10-04 |
| SI2922576T1 (en) | 2018-04-30 |
| EP3335735A1 (en) | 2018-06-20 |
| US9289406B2 (en) | 2016-03-22 |
| SMT201800022T1 (it) | 2018-03-08 |
| BR112015011778A2 (pt) | 2017-07-11 |
| JP2016506378A (ja) | 2016-03-03 |
| KR20150086510A (ko) | 2015-07-28 |
| CY1120163T1 (el) | 2018-12-12 |
| CN104797272A (zh) | 2015-07-22 |
| HK1210699A1 (en) | 2016-05-06 |
| EP2922576A1 (en) | 2015-09-30 |
| EP2922576A4 (en) | 2016-05-04 |
| HK1213778A1 (en) | 2016-07-15 |
| CA2891657A1 (en) | 2014-05-30 |
| US20140142186A1 (en) | 2014-05-22 |
| LT2922576T (lt) | 2018-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2018022I2 (el) | Πολυκυκλικες ενωσεις καρβαμοϋλπυριδονης και φαρμακευτικη χρηση αυτων | |
| PL2922576T3 (pl) | Sposoby podawania i oceny leków wychwytujących azot do leczenia encefalopati wątrobowej | |
| DK3639872T3 (da) | Lægemiddeladministrationsanordning | |
| EP3065808C0 (en) | DEVICES AND METHODS FOR CONTINUOUS ORAL DRUG DELIVERY | |
| LT2986304T (lt) | Farmacinė kompozicija, gydymo būdai ir jų panaudojimas | |
| IL230786A0 (en) | Heterocyclic derivative and pharmaceutical drug | |
| EP2922877A4 (en) | IMPROVED PEPTIDATE MEDICINES | |
| HRP20181855T1 (hr) | Lipidi za formulacije namijenjene unosu terapijskog sredstva | |
| BR112016009485A2 (pt) | Inalador de medicamento | |
| IL244089A0 (en) | Diagnostic methods and compositions for treatment of glioblastoma | |
| EP2804599A4 (en) | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS | |
| PL2842945T3 (pl) | Pochodna sulfonamidowa i jej zastosowanie medyczne | |
| IL229963A0 (en) | Substituted quinolines and their use as medicaments | |
| IL312551A (en) | Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer | |
| IL235768A0 (en) | Pharmaceutical compositions and treatment of mastitis | |
| PT3064491T (pt) | Derivado de sulfonamida e sua utilização medicinal | |
| PT2968368T (pt) | Administração craniana de substâncias farmacêuticas | |
| IL262252B (en) | Therapeutic compositions and methods involving mrna transfection | |
| IL234606B (en) | Novel methods and composition for treatment of disease | |
| DK3079655T3 (da) | Inhalerbare lægemidler | |
| HRP20190050T1 (hr) | Farmaceutski pripravci za kombinacijsku terapiju | |
| DK2964193T3 (da) | Lægemidler til oral indgivelse | |
| IL233875A (en) | Composition and use thereof in the treatment of anal rhagades | |
| DK3473255T3 (da) | Farmaceutisk formulering omfattende ciclesonid | |
| DK2897588T3 (da) | Inhalerbart lægemiddel |